 |
|
|
| |
Safety and Efficacy of Glecaprevir / Pibrentasvir in Patients with Chronic Hepatitis C Genotypes 1 - 6 and Recent Drug Use
|
| |
| |
Reported by Jules Levin
AASLD - The Liver Meeting: 68th Annual Meeting of the American Association for the Study of Liver Diseases, 21 October 2017, Washington, DC, USA
Graham R Foster1, Jason Grebely2, Kenneth Sherman3, Stanley Wang4, Gregory J Dore2, Axel Baumgarten5, Brian Conway6, Daniel Jackson7, Tarik Asselah8, Michael Gschwantler9, Krzysztof Tomasiewicz10, Humberto Aguilar11, Armen Asatryan4, N Niki Alami4, Emily Dumas4, Yiran Hu4, Federico J Mensa41Hepatology Unit, Queen Mary University of London, London, UK; 2The Kirby Institute, UNSW Sydney, Sydney, Australia; 3Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH, USA; 4AbbVie, North Chicago, IL, USA; 5Center for Infectiology, Berlin, Germany; 6Vancouver Infectious Diseases Centre, Vancouver, Canada; 7Digestive Health Specialists of the Southeast, Dothan, AL, USA; 8Universite Paris Diderot, AP-HP Hopital Beaujon, Clichy, France; 9Department of Internal Medicine IV, Wilhelminenspital, Vienna, Austria; 10Medical University of Lublin, Lublin, Poland; 11Louisiana Research Center, Shreveport, LA, USA
|
| |
|
|
|
|
|
